Quantum BioPharma Ltd. January 2025 Form 6-K: Investor Insights & Compliance Update

Here are the key insights extracted from the financial report:

1. Filing Type: This is a Form 6-K, which is typically filed by foreign private issuers to provide information that is material to investors.
2. Company Information:

• Name: Quantum BioPharma Ltd.
• Address: 55 University Ave., Suite 1003, Toronto, Ontario, Canada, M5J2H7.

3. Reporting Period: The report is for the month of January 2025.
4. Commission File Number: 001-39152.
5. Annual Report Filing: The registrant indicates that it files annual reports under Form 20-F.
6. Signature:

• The report was signed by Donal Carroll, who is the Chief Financial Officer of Quantum BioPharma Ltd.
• Date of Signature: January 7, 2025.

7. Exhibit Index:

• Exhibit 99.1: Includes a press release related to the company, indicating that there may be additional material information provided in that document.

This report is primarily an administrative update, indicating compliance with SEC regulations for foreign private issuers. The specific details about the content of the press release or any financial performance metrics are not provided in this section but may be elaborated in the referenced exhibit.